Bitdeer Technologies Group vs Medpace Holdings Inc — how do they compare? Bitdeer Technologies Group trades at $8.97 (market cap $2.36B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 7.2× Bitdeer Technologies Group's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | MEDP | |
|---|---|---|
Market Cap | $2.36B | $16.90B |
Sector | Technology | Technology |
52-Week High | $25.90 | $620.59 |
52-Week Low | $7.28 | $393.42 |
Enterprise Value | $3.85B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.18, up 5.58% today but facing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported Q2 2026 revenue growth but missed EPS expectations for the fourth consecutive quarter with a loss of $0.37 per share. Recent developments include a significant $4.7 billion AI data center deal announced August 4, 2026, signaling strategic expansion beyond Bitcoin mining into AI infrastructure.
Despite analyst optimism with 82% buy ratings and a $22.43 consensus price target, fundamental challenges persist including negative net income margin (-28.14%) and cash flow concerns. The stock offers substantial upside potential if AI initiatives succeed but faces execution risk amid volatile cryptocurrency markets and competitive pressures in the infrastructure sector.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →